FLT3 and acute myeloid leukemia: In a recent study, FLT3-mutation positive relapsed or refractory AML CHRYSALIS Phase I/II study patients were analysed for their TKI-response to Gilteritinib (ASP2215; clincal trail number: NCT02014558 [60]).